Table 3.
Synopsis of published and present results about rechallenged sunitinib
| Study | n | CK [%] | First sunitinib | Between | Rechallenged sunitinib | mOS (mo) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Reference number | OR (CB) | mPFS (mo) | mTOR [%] | TKI [%] | Both [%] | OR (CB) | mPFS (mo) | |||
| [9] | 52 | – | 54 (94) | 18.4 | 15 | 4 | 78 | 15 (61) | 7.9 | 55.9 |
| [15] | 39 | 0 | – (100) | > 10 | 100 | 0 | 0 | – | 8.6 | – |
| [10] | 23 | 73 | 65 (94) | 13.7 | 26 | 35 | 13 | 21 (92) | 7.2 | – |
| [11] | 13 | 62 | 69 (92) | 21 | 85 | 0 | 15 | 15 (92) | 6.9 | NR |
| [8] | 5 | 0 | – (100) | 11.5 | 60 | 0 | 40 | 0 (100) | 6.4 | – |
| [12] | 1 | 0 | 0 (100) | 9 | 0 | 0 | 100 | 0 (100) | > 8 | >23 |
| [13] | 1 | 100 | 0 (100) | 4 | 100 | 0 | 0 | 100 | 7 | >38 |
| [14] | 1 | 0 | 100 | 18 | 100 | 0 | 0 | 100 (100) | > 7 | >30 |
| Present | 21 | 52 | 38 (86) | 22 | 38 | 33 | 29 | 19 (76) | 14 | 67 |
CB clinical benefit rate, CK cytokine treatment before first sunitinib, italics prospective study, mo months, mOS median overall survival, mPFS median progression-free survival, mTOR mTOR pathway inhibitor, NR not reached, OR objective response rate, TKI tyrosine kinase inhibitor (other than sunitinib)